Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06555133 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Y-90, Capecitabine, and Atezolizumab for Oligometastatic CRC

Study acronym: METEORITE
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated August 20, 2026 (before its estimated September 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Re-verified, no change to tracked fieldsv6
  2. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Mar 1, 2025 to Apr 7, 2025
    v5
  3. Start date: Dec 30, 2024 to Mar 1, 2025v4
  4. Start date: Aug 30, 2024 to Dec 30, 2024v3
  5. Secondary endpoints: details revised at 2 of 3 entriesv2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
BrUOG-430 is a prospective, single-arm, phase 2 trial evaluating yttrium-90 radioembolization in combination with capecitabine and atezolizumab for the treatment of unresectable colorectal cancer liver metastases in individuals who have been treated with two or more lines of systemic therapy.
Trial Details
NCT Number NCT06555133
Lead Sponsor Brown University
Collaborators: Sirtex Medical, Genentech, Inc.
Conditions
(from sponsor)		 Colorectal Carcinoma Metastatic in the Liver
Enrollment 18 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov